We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
Cap. Flow
-$10.3M
Cap. Flow %
-0.37%
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.7M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$13.3M
5
JNJ icon
Johnson & Johnson
JNJ
+$11.2M

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$23.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$12.8M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
AMGN icon
Amgen
AMGN
+$11.4M
5
AKRX
Akorn Inc
AKRX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Real Estate 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
51
Edwards Lifesciences
EW
$50B
$10.6M 0.38%
+292,200
New +$11.1M
CTMX icon
52
CytomX Therapeutics
CTMX
$714M
$9.63M 0.34%
530,092
– –
DPLO
53
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$9.56M 0.34%
461,712
– –
MRUS
54
DELISTED
Merus
MRUS
$9.52M 0.34%
479,150
– –
EXEL icon
55
Exelixis
EXEL
$14.1B
$9.42M 0.34%
388,822
-162,825
-30% -$4.33M
DOC
56
DELISTED
PHYSICIANS REALTY TRUST
DOC
$9.41M 0.34%
530,672
– –
ABBV icon
57
AbbVie
ABBV
$455B
$9.29M 0.33%
104,513
+104,300
+48,967% +$7.94M
NUVA
58
DELISTED
NuVasive, Inc.
NUVA
$8.96M 0.32%
+161,576
New +$10.7M
SNY icon
59
Sanofi
SNY
$103B
$8.96M 0.32%
179,900
– –
CLLS
60
Cellectis
CLLS
$287M
$8.83M 0.32%
310,250
– –
EPZM
61
DELISTED
Epizyme, Inc
EPZM
$8.69M 0.31%
456,000
+175,000
+62% +$2.67M
ELV icon
62
Elevance Health
ELV
$81.6B
$8.53M 0.3%
+44,918
New +$8.55M
KPTI icon
63
Karyopharm Therapeutics
KPTI
$159M
$8.31M 0.3%
50,445
– –
ZBH icon
64
Zimmer Biomet
ZBH
$18.4B
$7.94M 0.28%
69,834
-35,535
-34% -$4.1M
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$2.56B
$7.91M 0.28%
148,558
+21,250
+17% +$1.26M
ENDP
66
DELISTED
Endo International plc
ENDP
$7.83M 0.28%
914,548
– –
PRAH
67
DELISTED
PRA Health Sciences, Inc.
PRAH
$7.77M 0.28%
102,000
– –
ADAP
68
DELISTED
Adaptimmune Therapeutics
ADAP
$7.66M 0.27%
935,368
-531,000
-36% -$3.32M
HCA icon
69
HCA Healthcare
HCA
$85.7B
$7.58M 0.27%
95,232
– –
TSRO
70
DELISTED
TESARO, Inc.
TSRO
$7.44M 0.27%
+57,595
New +$7.15M
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.15M 0.26%
+123,200
New +$13.3M
WMGI
72
DELISTED
Wright Medical Group Inc
WMGI
$6.9M 0.25%
266,781
+52,000
+24% +$1.43M
AVDL
73
DELISTED
Avadel Pharmaceuticals
AVDL
$6.55M 0.23%
624,288
– –
LTC
74
LTC Properties
LTC
$2.06B
$6.4M 0.23%
136,212
– –
ENTL
75
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
$6.3M 0.23%
341,471
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
  • Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
  • Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
  • Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
  • Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
  • Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.